当前位置: 首页 >> 检索结果
161. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
作者: Kristin A Shimano.;Amanda B Grimes.;Shipra Kaicker.;Sanjay J Shah.;Elizabeth Gunn.;Rukhmi V Bhat.;Manpreet Kochhar.;Jennifer A Rothman.;Melissa J Rose.;Michael Briones.;Taizo A Nakano.;Jeffrey D Lebensburger.;Michele P Lambert.;Stephanie A Fritch Lilla.;Rohith Jesudas.;Cathy A Lee-Miller.;Alexis A Thompson.;Stacey Rifkin-Zenenberg.;Suvankar Majumdar.;Shelley E Crary.;Kerry Hege.;James B Ford.;Joshua J Bies.;John Fort.;Tung T Wynn.;Loan Hsieh.;Maritza E Ruiz.;Bogdan Dinu.;Julia M W Wong.;Pei-Chi Kao.;Taylor O Kim.;Staci D Arnold.;Carolyn M Bennett.;Jenny M Despotovic.;Robert J Klaassen.;Ellis J Neufeld.;Cindy E Neunert.;Wendy B London.;Rachael F Grace.
来源: JAMA. 2025年
Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown.
173. Lung Cancer in Nonsmoking Individuals: A Review.
Lung cancer in nonsmoking individuals (defined as people who have smoked fewer than 100 cigarettes in their lifetime) accounts for 15% to 20% of all lung cancer cases worldwide. In the US, the annual incidence of lung cancer in nonsmoking individuals is 14.4 to 20.8 per 100 000 person-years in females and 4.8 to 12.7 per 100 000 person-years in males.
174. A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial.
作者: David P Miller.;Anna C Snavely.;Ajay Dharod.;Alison T Brenner.;Elena Wright.;Lindsay Stradtman.;Christina R Bellinger.;Richa Bundy.;Robert J Volk.;Emily Hamburger.;Renée M Ferrari.;Aliza Randazzo.;Daniel S Reuland.
来源: JAMA. 2025年
Screening chest computed tomography (CT) scans reduce lung cancer mortality in high-risk individuals, but less than 20% of eligible individuals are screened in the US.
|